OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.95 EUR 0.17% Market Closed
Market Cap: 133m EUR

EV/EBIT
Enterprise Value to EBIT

3.5
Current
-4.6
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
3.5
=
Enterprise Value
151.9m EUR
/
EBIT
43.7m EUR
EBIT Growth EV/EBIT to Growth
FR
OSE Immunotherapeutics SA
PAR:OSE
Average EV/EBIT: 17.8
3.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 350.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.9
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -539.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.6
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -315.7 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
9
2-Years Forward
EV/EBIT
-5.4
3-Years Forward
EV/EBIT
-124.3